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CCR5 and CXCR3 are chemokine receptors expressed predominantly on Thl cells and have been implicated in 
their migration to sites of inflammation. Because T cell migration to sites of inflammation is a key process of 
sequential inflammatory responses, this process could be a target for the control of various inflammatory 
diseases. In this context, our preceding study demonstrated that a non-peptide synthetic CCR5 antagonist 
TAK.-779 inhibited the development of experimentally induced arthritis in the mouse model by down-regulating 
the migration of T cells to joints. However, since almost al of the joints-infiltrating T cells were found to 
express CXCR3 (CXCR3+ or CXCR3+/CCR5+) , a question remains to be answered is whether the 
down-regulation of the joint recruitment of T cells by TAK-779 is only via affecting CCR5 function. To address 
this question, we established a set of transfectants expressing mouse chemokine receptors CCR5, CXCR3, CCR4 
or CXCR4 and investigated the target receptor speci五city ofTAK-779. 
Methods 
The stable transfectants expressing mouse chemokine receptors CCR5, CXCR3, CCR4 or CXCR4 were 
established by transfection of each relevant gene into 2B4 T cells, using retroviral expression vectors. The 
transfectants were then subjected to the following assays to investigate the target receptor specificity ofTAK-779. 
First, the ligand binding to chemokine receptors was assayed by incubating transfectants with [125・l]-labeled
relevant ligand followed by gamma counting of the cell-associated radioactivity, or by incubating the 
transfectants with the unlabeled relevant ligand followed by staining with anti-ligand Ab. Secondly, 
chemokine-induced LFA-l activation was assayed by measuring the adhesion of cells to microculture plates 
coated with puri五ed ICAM-1. Thirdly, chemokine-stimulated chemotaxis was assayed by observing the cell 





Fi1'st, we established the stable t1'ansfectants exp1'essing mouse CCR5, CXCR3, CCR4 01' CXCR4, 1'espectively. 
The 1'esults of FACS staining showed that these t1'ansfectants exp1'ess the 1'elevant chemokine 1'eceptors which 
function as the binding 1'ecepto1's of the corresponding chemokines. Secondly, we examined the functionality of 
the chemokine 1'ecepto1's exp1'essed on these t1'ansfectants in cell adhesion and chemotaxis assays. CCR5 and 
CXCR3 t1'ansfectants exhibited simila1' dose 1'esponses in the adhesiol1 to ICAM-1 whel1 stimulated with the 
1'elevant chelllokines (RANTES, MIP-1αal1d MIP-1/3 fo1' CCR5 ; lP-10, MIG and l-TAC fo1' CXCR3). ln 
chelllotaxis assays, both CCR5 al1d CXCR3 t1'al1sfectal1ts also displayed chemotactic 1'espOl1ses whel1 stimulated 
with 1'eleval1t chelllOkil1es although the doses of chelllokines 1'equi1'ed for the peak responses were differel1t for 
CCR5 and CXCR3. CCR4 and CXCR4 transfectants respol1ded silllilarly whel1 stilllulated with 1'eleval1t 
chelllokines. These results indicated that the transfectants p1'epa1'ed he1'e exp1'ess functional chelllokine 
recepto1's. Thirdly, we examined the effect of TAK-779 on ligand-binding of CCR5, CXCR3, CCR4 and CXCR4. 
Preincubation with TAK-779 ef:iciently blocked the ligand-binding of CCR5 and CXCR3, with the comparable 
lC50 of 236 nM fo1' CCR5 and 369 nM for CXCR3. However, p1'eincubation with TAK-779 did not exe1't 
inhibito1'Y e町ects on the ligand-binding of CCR4 and CXCR4. Fou1'thly, we examined the e百ect of TAK-779 on 
the function of CCR5, CXCR3, CCR4 and CXCR4 as assessed by the binding to lCAM-1 and chemotaxis. The 
1'esults demonstrated that p1'eincubation of CCR5 01' CXCR3 t1'ansfectants with TAK-779 1'esulted in a 
dose-dependent inhibition of the 1'elevant chemokine-mediated cell-adhesion and chemotaxis. ln cont1'ast, this 
antagonist induced only slight 01' marginal inhibition of CCR4・ 01' CXCR4-mediated cell adhesion and 
chemotaxis. 
Conclusion 
The p1'esent study demonst1'ated that TAK-779 blocks the function of CXCR3 and CCR5 as assessed by the 
ligand binding assays, cell adhesion assays and chemotaxis. ln cont1'ast, it does 10t elicit biologically significant 
inhibition on those of CCR4 and CXCR4. These obse1'vations indicate the unique targ1't specificity of TAK-779 
and p1'ovide a mechanistic explanation fo1' its efficient blockade of Th1 cell migration to infla血matorylesions. 
論文審査の結果の要旨
ケモカイン受容体 CCR5 と CXCR3 は、 Th1 細胞の炎症局所への浸潤に重要な役割を果たすことが示唆されてきた。
当教室では、 CCR5 特異的阻害剤として開発された TAK-779 の投与により、腫場局所への T 細胞浸潤が抑制され、
腫療拒絶が阻止されることを報告してきた。この抑制効果が CCR5 のみの阻害に基づくものか否かを検討する為に、
本研究では、 TAK-779 の標的受容体特異性を調べ、以下の結果を得た。
(1)マウス 2B4T 細胞株において CCR5 、 CCR3 、 CCR4 及び CXCR4 遺伝子を導入し、 transfectants を作成した。
(2)ligand binding assay, cell adhesion assay, chemotaxis assay により TAK-779 の阻害効果を調べた。その結果、
TAK-779 は CCR5 と CXCR3 に対してほぼ同等の抑制効果を示した。一方、対照としての CCR4 及び CXCR4 には
ほとんど有意な抑制を示さなかった。
以上より本研究は、 TAK-779 が Th1 細胞に発現されるケモカイン受容体 (CCR5 と CXCR3) に特異的な抑制効果
を示すという興味深い知見を提供すると共に、 T 細胞の炎症局所浸潤を効果的に抑制する機構を説明しうるため、学
位論文に値するものと考える。
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